The collaboration will allow Shriners Hospitals to provide DNA samples from patients to JAX, which will then develop mouse models with the same genetic code–including conditions– as the patients to advance research. Both JAX and Shriners Hospitals hope the new research tool will enable specific gene therapies for rare diseases that can bear permanent results.
“Harnessing the power of genomics to understand the basis for orthopedic and other pediatric diseases is of the utmost importance,” said Charles Lee, PhD, FACMG, scientific director and professor at JAX. “This research can bring hope to countless families, and we’re looking forward to working with Shriners Hospitals to help children around the world.”
NEC congratulates both Shriners Hospitals and JAX for their work to improve children’s lives. Read more.
Recently from the Blog
November 24 Weekly Round-Up: NEC Members Contribute to COVID-19 Crisis Response